Biweekly docetaxel and carboplatin as first-line therapy in patients with advanced non-small cell lung cancer (NSCLC). Finally results of a phase II study
2008 ◽
Vol 26
(15_suppl)
◽
pp. 19097-19097
Keyword(s):
Phase Ii
◽